Described here are three ODYSSEY Phase 3 trials , FH I ( NCT01623115 ) , FH II ( NCT01709500 ) and HIGH FH ( patients with heFH and LDL-C levels 160mg/dL ) ( NCT01617655 ) , in which alirocumab is further evaluated in the heFH population .